What is the scale and purpose of GSK's £1.9bn cost-cutting plan, and how does it relate to its UK life sciences investment?

GSK’s £1.9bn cost-cutting plan is designed to fund a £400m investment in UK life sciences over three years, including building a new 300,000-sq ft R&D centre in Cambridge. The plan supports faster drug development under new CEO Luke Miels, with savings coming largely from cutting support services (45%), streamlining procurement and processes, and reallocating resources away from established treatments toward new drug development (40%).

Where will GSK relocate its scientists, and what is happening to its existing UK R&D sites?

GSK will move more than 1,000 scientists to its new R&D site on the Cambridge biomedical campus and close its Stevenage (Hertfordshire) R&D site by 2029, while upgrading laboratories in nearby Ware and relocating some staff there.

GSK to Cut Jobs Amid £1.9bn Cost-Cutting Plan and Bid for Faster Drug Development

Jul 28, 2026

GSK plans to cut over 1,000 jobs and close its Stevenage R&D site to fund a £400m investment in Cambridge, accelerating drug development in areas like oncology and vaccines.

theguardian

2026-07-28

GSK to Cut Jobs Amid £1.9bn Cost-Cutting Plan and Bid for Faster Drug Development

GSK to Cut Jobs Amid £1.9bn Cost-Cutting Plan and Bid for Faster Drug Development

FAQ